Royalty Pharma plc (RPRX)

Royalty Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	2,264	2,264	2,355	2,237	2,289	2,122
Revenue Growth (YoY)	1.13%	-3.86%	5.24%	-2.28%	7.87%	16.98%
Cost of Revenue	21.72	732.46	560.66	904.24	452.84	230.84
Gross Profit	2,242	1,531	1,794	1,333	1,837	1,892
Selling, General & Admin	289.72	236.67	249.75	227.3	182.83	181.72
Research & Development	52	2	52	177.11	200.08	26.29
Operating Expenses	341.72	238.67	301.75	410.08	405.91	231.06
Operating Income	1,900	1,292	1,492	922.89	1,431	1,660
Interest Expense	-246.54	-225.51	-187.19	-187.96	-166.14	-167.96
Interest & Investment Income	51.22	47.34	72.29	78.34	53.54	28.38
Earnings From Equity Investments	50.2	29.61	28.88	-8.97	-19.49	44.46
Other Non Operating Income (Expenses)	-7.91	-7.53	-24.03	81.86	-27.21	-33.5
EBT Excluding Unusual Items	1,747	1,136	1,382	886.15	1,271	1,532
Gain (Loss) on Sale of Investments	21.15	194.46	317.98	-40.26	-30.21	265.67
Asset Writedown	-	-	-	-615.83	-	-65.05
Other Unusual Items	-	-	-	-	-	-30.5
Pretax Income	1,769	1,331	1,700	230.06	1,241	1,702
Earnings From Continuing Operations	1,769	1,331	1,700	230.06	1,241	1,702
Minority Interest in Earnings	-675.97	-471.83	-565.25	-187.23	-621.47	-726.91
Net Income	1,093	858.98	1,135	42.83	619.73	975.04
Preferred Dividends & Other Adjustments	-	-	-	-	-	479.84
Net Income to Common	1,093	858.98	1,135	42.83	619.73	495.2
Net Income Growth	36.77%	-24.31%	2549.50%	-93.09%	-36.44%	-58.48%
Shares Outstanding (Basic)	445	448	448	438	415	375
Shares Outstanding (Diluted)	589	594	603	438	415	375
Shares Change (YoY)	-1.86%	-1.46%	37.66%	5.59%	10.48%	-
EPS (Basic)	2.46	1.92	2.54	0.10	1.49	1.32
EPS (Diluted)	2.45	1.91	2.53	0.10	1.49	1.32
EPS Growth	37.60%	-24.54%	2490.74%	-93.44%	12.97%	-
Dividend Per Share	0.850	0.840	0.800	0.760	0.680	0.300
Dividend Growth	4.94%	5.00%	5.26%	11.77%	126.67%	-
Gross Margin	99.04%	67.64%	76.19%	59.58%	80.22%	89.12%
Operating Margin	83.95%	57.10%	63.37%	41.25%	62.49%	78.24%
Profit Margin	48.26%	37.95%	48.20%	1.92%	27.07%	23.33%
EBITDA	-	-	1,498	928.56	1,454	1,684
EBITDA Margin	-	-	63.61%	41.50%	63.50%	79.32%
D&A For EBITDA	-	-	5.67	5.67	23	23.06
EBIT	1,900	1,292	1,492	922.89	1,431	1,660
EBIT Margin	83.95%	57.10%	63.37%	41.25%	62.49%	78.24%
Revenue as Reported	2,264	2,264	2,355	2,237	2,289	2,122

Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q